Politics

/

ArcaMax

Editorial: A hopeful step for Parkinson's patients

Star Tribune Editorial Board, Star Tribune on

Published in Op Eds

It began with a teacup and saucer at a work event. It was 2010, and Sherrie Pugh picked up the offending objects, but, before she could get coffee, the uncontrollable rattling prompted a helpful staffer to intervene. A function Pugh thought she'd have for life, that of pouring coffee: gone. It would take five years of tremors, and countless doctor visits in that time, before Pugh, now 73, would receive a Parkinson's diagnosis.

The case of Pugh's is hardly out of the ordinary. Parkinson's disease, despite its potentially debilitating nature, is notoriously difficult to diagnose, with many patients suffering for years before receiving proper diagnosis and treatment.

So the optimism with which the National Plan to End Parkinson's Act, signed into law by President Joe Biden on July 2, has been received nationwide, is understandable. This is a welcome development for the Parkinson's community and long overdue. The legislation directs the U.S. Department of Health and Human Services to develop a national plan to better diagnose and treat the disease, as well as prevent it.

In addition, it establishes an advisory council to assist federal officials. The bill's passage also puts a helpful spotlight on the disorder, yielding greater awareness of Parkinson's and encouragement for patients like Pugh, who lives in Mound.

This act was modeled off the 2011 National Alzheimer's Project Act, which laid the groundwork for public investments of over $3.8 billion in federal revenue to combat Alzheimer's. While it's a shame that it has taken over a decade for the government to make a similar commitment to fighting Parkinson's (which received $259 million in research funding from the NIH in 2022), hopefully the same investment and attention that followed the Alzheimer's bill will be devoted to Parkinson's in the wake of this new bill.

The bill, backed by strong bipartisan support, calls for improved treatments and cures, furthering federal support for research and promoting preventive measures. The targeted approach has the potential to change the way millions experience this debilitating neurodegenerative disease, whose symptoms include tremors, mobility problems and cognitive decline.

Currently, over 1 million Americans suffer nationwide, with 20,000 Minnesotans currently afflicted. The disease's total economic burden is $52 billion nationwide annually, according to 2023 data. Patients can also face thousands in medical bills for care.

"It's great that it's become a national initiative, because it's become a national problem," James Miller, 69, a resident of Edina and Parkinson's patient said in an interview with an editorial writer. Miller, too, has undergone a lengthy diagnosis and treatment journey marked by medication adjustments, deep brain surgery and corresponding lifestyle changes.

 

Leslie A. Chambers, president and CEO of the American Parkinson Disease Association, similarly lauded the lawmakers effort: "We are emboldened by this new law and optimistic about this federal focus on curing and preventing Parkinson's disease."

Rep. Gus Bilirakis, R-Fla., in the U.S. House and Sen. Shelley Moore Capito, R- W.V., served as the lead authors in Congress. Despite the bill's inspiring goals and commitments, it's light on the details. It declares a commitment in only the most general terms, leaving researchers, patients and their families optimistic, but not entirely certain of exactly what this bill will mean for them, and whether the funding will follow in the same way it did with the Alzheimer's legislation. Still, the legislation's passage and the battle plan it will yield should galvanize support and public investment.

Dr. Jerrold Vitek, head of the Neurology Department at the University of Minnesota Medical School and director of the Udall Center of Excellence for Parkinson's Disease Research, described some of the challenges currently faced by Parkinson's researchers, and how the efforts of this bill, if appropriately directed, can positively impact the research.

Vitek notes that it is a very difficult, lengthy and highly competitive process to get money to fund research. If a grant is even awarded in the first place, it frequently endures annual "routine cuts" of around 17.5% annually. This bill, if it provides appropriate funding to the right institutions, has the potential to help fulfill research breakthroughs that can improve Parkinson's diagnosis and treatment. "A lot of really good grants just don't quite make it," Vitek said in discussion with an editorial writer. "When you have more money available, you can fund more of these grants."

Some of these breakthroughs are closer than many think. With the advent of artificial intelligence, there's promising research being conducted at Duke University, with the possibility of diagnosing people before they show symptoms by looking at a constellation of proteins from a blood test.

"If you can stop the progression of disease prior to symptoms, it would be tremendous," Vitek said. With promising research being conducted across the country, and now the pledge of additional federal support, this bill marks a hopeful page turn in the battle against Parkinson's disease.

_____


©2024 StarTribune. Visit at startribune.com. Distributed by Tribune Content Agency, LLC.

 

Comments

blog comments powered by Disqus

 

Related Channels

ACLU

ACLU

By The ACLU
Amy Goodman

Amy Goodman

By Amy Goodman
Armstrong Williams

Armstrong Williams

By Armstrong Williams
Austin Bay

Austin Bay

By Austin Bay
Ben Shapiro

Ben Shapiro

By Ben Shapiro
Betsy McCaughey

Betsy McCaughey

By Betsy McCaughey
Bill Press

Bill Press

By Bill Press
Bonnie Jean Feldkamp

Bonnie Jean Feldkamp

By Bonnie Jean Feldkamp
Cal Thomas

Cal Thomas

By Cal Thomas
Christine Flowers

Christine Flowers

By Christine Flowers
Clarence Page

Clarence Page

By Clarence Page
Danny Tyree

Danny Tyree

By Danny Tyree
David Harsanyi

David Harsanyi

By David Harsanyi
Debra Saunders

Debra Saunders

By Debra Saunders
Dennis Prager

Dennis Prager

By Dennis Prager
Dick Polman

Dick Polman

By Dick Polman
Erick Erickson

Erick Erickson

By Erick Erickson
Froma Harrop

Froma Harrop

By Froma Harrop
Jacob Sullum

Jacob Sullum

By Jacob Sullum
Jamie Stiehm

Jamie Stiehm

By Jamie Stiehm
Jeff Robbins

Jeff Robbins

By Jeff Robbins
Jessica Johnson

Jessica Johnson

By Jessica Johnson
Jim Hightower

Jim Hightower

By Jim Hightower
Joe Conason

Joe Conason

By Joe Conason
Joe Guzzardi

Joe Guzzardi

By Joe Guzzardi
John Micek

John Micek

By John Micek
John Stossel

John Stossel

By John Stossel
Josh Hammer

Josh Hammer

By Josh Hammer
Judge Andrew Napolitano

Judge Andrew Napolitano

By Judge Andrew P. Napolitano
Laura Hollis

Laura Hollis

By Laura Hollis
Marc Munroe Dion

Marc Munroe Dion

By Marc Munroe Dion
Michael Barone

Michael Barone

By Michael Barone
Michael Reagan

Michael Reagan

By Michael Reagan
Mona Charen

Mona Charen

By Mona Charen
Oliver North and David L. Goetsch

Oliver North and David L. Goetsch

By Oliver North and David L. Goetsch
R. Emmett Tyrrell

R. Emmett Tyrrell

By R. Emmett Tyrrell
Rachel Marsden

Rachel Marsden

By Rachel Marsden
Rich Lowry

Rich Lowry

By Rich Lowry
Robert B. Reich

Robert B. Reich

By Robert B. Reich
Ruben Navarrett Jr

Ruben Navarrett Jr

By Ruben Navarrett Jr.
Ruth Marcus

Ruth Marcus

By Ruth Marcus
S.E. Cupp

S.E. Cupp

By S.E. Cupp
Salena Zito

Salena Zito

By Salena Zito
Star Parker

Star Parker

By Star Parker
Stephen Moore

Stephen Moore

By Stephen Moore
Susan Estrich

Susan Estrich

By Susan Estrich
Ted Rall

Ted Rall

By Ted Rall
Terence P. Jeffrey

Terence P. Jeffrey

By Terence P. Jeffrey
Tim Graham

Tim Graham

By Tim Graham
Tom Purcell

Tom Purcell

By Tom Purcell
Veronique de Rugy

Veronique de Rugy

By Veronique de Rugy
Victor Joecks

Victor Joecks

By Victor Joecks
Wayne Allyn Root

Wayne Allyn Root

By Wayne Allyn Root

Comics

Lisa Benson Ed Wexler Christopher Weyant Gary McCoy Mike Beckom Andy Marlette